DiaMedica Therapeutics Inc.
DMAC
$6.05
$0.091.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 28.32% | 17.49% | 8.82% | -3.27% | -6.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.92% | 39.37% | 40.52% | 35.36% | 25.46% |
| Operating Income | -28.92% | -39.37% | -40.52% | -35.36% | -25.46% |
| Income Before Tax | -34.10% | -47.26% | -48.81% | -40.35% | -26.25% |
| Income Tax Expenses | -6.67% | -37.21% | -34.88% | -32.56% | -30.23% |
| Earnings from Continuing Operations | -34.05% | -47.09% | -48.63% | -40.19% | -26.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.05% | -47.09% | -48.63% | -40.19% | -26.12% |
| EBIT | -28.92% | -39.37% | -40.52% | -35.36% | -25.46% |
| EBITDA | -28.95% | -39.40% | -40.57% | -35.36% | -25.45% |
| EPS Basic | -16.27% | -29.78% | -31.83% | -16.74% | 2.46% |
| Normalized Basic EPS | -16.36% | -29.94% | -31.97% | -16.81% | 2.42% |
| EPS Diluted | -16.27% | -29.78% | -31.83% | -16.74% | 2.46% |
| Normalized Diluted EPS | -16.36% | -29.94% | -31.97% | -16.81% | 2.42% |
| Average Basic Shares Outstanding | 16.25% | 13.68% | 12.74% | 17.87% | 24.56% |
| Average Diluted Shares Outstanding | 16.25% | 13.68% | 12.74% | 17.87% | 24.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |